EGFR inhibitors
AstraZeneca's Tagrisso Gets Nod From EMA's CHMP in Unresectable EGFR-Mutated NSCLC
If approved by the EC, Tagrisso will be the first targeted therapy for European patients with unresectable EGFR-mutated cancer.
AstraZeneca, Daiichi Sankyo Launch Three New Lung Cancer Trials of Dato-DXd
The drugmakers will explore the efficacy of Dato-DXd in combination with other drugs in PD-L1-expressing or EGFR-mutated NSCLC in these studies.
Black Diamond Therapeutics Restructures Workforce, Deprioritizes RAF Program
The firm is focusing its resources on developing its lead candidate, the EGFR inhibitor BDTX-1535, which is undergoing testing in EGFR-mutated NSCLC.
AstraZeneca Nabs FDA Approval for Tagrisso in Stage III, Unresectable EGFR-Mutated NSCLC
The third-generation EGFR inhibitor will now be an option for patients whose tumors are not metastatic but can't be removed with surgery.
Merck, Daiichi Sankyo to Discuss Antibody-Drug Conjugate Data in EFGR-Mutated NSCLC With Regulators
The firms will share data from the HERTHENA-Lung02 trial, in which patritumab deruxtecan improved patients' progression-free survival versus chemo.
Oct 24, 2023